BAC and GE Healthcare Expand Product Offering
BAC BV has announced the addition of a new bioprocess affinity chromatography resin to GE Healthcare Life Sciences' portfolio of custom-designed media.
The FactorVII / FactorVIIa resin will be marketed under the name VIISelect and is the latest addition to our series of chromatography media developed for the purification of blood coagulants.
VIISelect started as a custom ligand design program to develop chromatography media for the highly selective purification of human FactorVII / FactorVIIa.
Following the discovery, GE Healthcare and BAC worked closely with the customer to develop the final media suitable for cGMP production of Factor VIIa.
The launch of VIISelect media now offers a ready-to-use solution for the manufacturing of recombinant FactorVII / FactorVIIa ensuring a high purity product in a single-step.
Factor VIIa plays an important role in the blood coagulation cascade and recombinant Factor VIIa is used to treat and prevent bleeding episodes in hemophilia A and B patients with inhibitors to Factor VIII or Factor IX, and in patients with acquired hemophilia. Increasingly it is being used to treat uncontrollable hemorrhages.
”I am very pleased that we now can offer VIISelect to the market in order to facilitate both efficient and quick purification of Factor VII by affinity based chromatography at both lab and Bioprocess scale.” Says Henrik Ihre, Director of Custom Design Media at GE Healthcare Life Sciences.
“We are very excited about this new product launch, once again demonstrating the broad applicability of our CaptureSelect technology”, commented Laurens Sierkstra, CEO of BAC, adding, “working together with GE Healthcare and industry partners has already resulted in a multitude of products that have been adopted for large scale manufacturing of biotherapeutics.”
Following the success of VIIISelect for the purification of Factor VIII, VIISelect complements the range of products designed to support the area of hemophilia.